STK10 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	32 studies	32% ± 11%	Explore
non-classical monocyte	21 studies	34% ± 14%	Explore
T cell	20 studies	28% ± 10%	Explore
CD8-positive, alpha-beta T cell	20 studies	27% ± 11%	Explore
regulatory T cell	19 studies	24% ± 8%	Explore
classical monocyte	18 studies	26% ± 10%	Explore
macrophage	18 studies	29% ± 15%	Explore
CD4-positive, alpha-beta T cell	17 studies	24% ± 8%	Explore
mature NK T cell	16 studies	25% ± 9%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	38% ± 11%	Explore
B cell	14 studies	20% ± 5%	Explore
CD16-negative, CD56-bright natural killer cell, human	14 studies	31% ± 7%	Explore
monocyte	13 studies	32% ± 16%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	25% ± 7%	Explore
endothelial cell	12 studies	26% ± 9%	Explore
gamma-delta T cell	12 studies	26% ± 6%	Explore
CD4-positive, alpha-beta memory T cell	11 studies	20% ± 4%	Explore
mucosal invariant T cell	11 studies	28% ± 9%	Explore
myeloid cell	11 studies	33% ± 16%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	10 studies	22% ± 6%	Explore
effector memory CD8-positive, alpha-beta T cell	10 studies	30% ± 7%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	9 studies	22% ± 9%	Explore
microglial cell	9 studies	32% ± 11%	Explore
dendritic cell	8 studies	32% ± 13%	Explore
effector CD8-positive, alpha-beta T cell	6 studies	22% ± 5%	Explore
lymphocyte	5 studies	47% ± 22%	Explore
mast cell	5 studies	26% ± 9%	Explore
effector memory CD4-positive, alpha-beta T cell	5 studies	25% ± 8%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	5 studies	30% ± 11%	Explore
neutrophil	4 studies	28% ± 13%	Explore
leukocyte	4 studies	39% ± 15%	Explore
exhausted T cell	4 studies	27% ± 11%	Explore
mononuclear phagocyte	4 studies	26% ± 9%	Explore
glutamatergic neuron	4 studies	26% ± 7%	Explore
plasmablast	3 studies	21% ± 2%	Explore
conventional dendritic cell	3 studies	38% ± 16%	Explore
hematopoietic precursor cell	3 studies	32% ± 13%	Explore
retina horizontal cell	3 studies	31% ± 9%	Explore
effector CD4-positive, alpha-beta T cell	3 studies	27% ± 3%	Explore
innate lymphoid cell	3 studies	24% ± 5%	Explore
GABAergic neuron	3 studies	27% ± 6%	Explore
alveolar macrophage	3 studies	38% ± 11%	Explore
memory B cell	3 studies	17% ± 2%	Explore
naive B cell	3 studies	19% ± 2%	Explore
plasmacytoid dendritic cell	3 studies	22% ± 5%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	14 studies	25% ± 7%	Explore
brain	6 studies	21% ± 4%	Explore
lung	4 studies	20% ± 5%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
intestine	100%	2694.62	962 / 966	99%	16.44	523 / 527
breast	100%	3633.17	459 / 459	98%	16.94	1098 / 1118
skin	98%	3263.51	1776 / 1809	100%	69.66	472 / 472
lung	100%	5862.60	578 / 578	98%	15.04	1130 / 1155
bladder	100%	2562.71	21 / 21	97%	15.13	491 / 504
thymus	98%	1852.02	640 / 653	98%	13.29	590 / 605
uterus	98%	1472.20	166 / 170	97%	12.58	444 / 459
stomach	95%	1705.95	342 / 359	99%	16.07	283 / 286
esophagus	88%	1606.98	1273 / 1445	100%	16.16	183 / 183
kidney	90%	1736.52	80 / 89	94%	17.36	850 / 901
adrenal gland	98%	1703.63	253 / 258	84%	8.80	193 / 230
prostate	92%	1549.49	226 / 245	73%	5.31	368 / 502
brain	40%	2002.88	1067 / 2642	98%	14.28	694 / 705
pancreas	30%	365.77	99 / 328	98%	21.25	175 / 178
liver	49%	644.41	110 / 226	76%	6.86	307 / 406
ovary	38%	463.54	68 / 180	85%	8.07	364 / 430
adipose	100%	4660.35	1204 / 1204	0%	0	0 / 0
eye	0%	0	0 / 0	100%	51.47	80 / 80
lymph node	0%	0	0 / 0	100%	64.70	29 / 29
peripheral blood	100%	19891.40	929 / 929	0%	0	0 / 0
spleen	100%	13216.69	241 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	98%	16.82	44 / 45
heart	85%	1274.72	731 / 861	0%	0	0 / 0
blood vessel	81%	1399.78	1078 / 1335	0%	0	0 / 0
muscle	22%	231.29	173 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0006468	Biological process	protein phosphorylation
GO_0046777	Biological process	protein autophosphorylation
GO_2000401	Biological process	regulation of lymphocyte migration
GO_0071593	Biological process	lymphocyte aggregation
GO_0070062	Cellular component	extracellular exosome
GO_0005829	Cellular component	cytosol
GO_0035579	Cellular component	specific granule membrane
GO_0005886	Cellular component	plasma membrane
GO_0005737	Cellular component	cytoplasm
GO_0042803	Molecular function	protein homodimerization activity
GO_0004674	Molecular function	protein serine/threonine kinase activity
GO_0005515	Molecular function	protein binding
GO_0042802	Molecular function	identical protein binding
GO_0106310	Molecular function	protein serine kinase activity
GO_0005524	Molecular function	ATP binding

IV. Literature review

[source]

Gene name	STK10
Protein name	Serine/threonine-protein kinase 10 (EC 2.7.11.1) (Lymphocyte-oriented kinase) non-specific serine/threonine protein kinase (EC 2.7.11.1)
Synonyms	LOK
Description	FUNCTION: Serine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a negative regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator by acting as a polo kinase kinase: mediates phosphorylation of PLK1 in vitro; however such data require additional evidences in vivo. .
Accessions	ENST00000520476.1 O94804 H0YB71 ENST00000176763.10

STK10 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review